organization · Reporting owner
Graf Acquisition Partners IV LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NKGen Biotech, Inc.NKGN · Entity 79017 | 10% owner | December 20, 2024 | December 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NKGen Biotech, Inc.
Report date December 20, 2024 · Filed December 26, 2024
Jointly reported with Graf James A
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,082,507 |
Reported balance
After 2024-12-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-20 · Other · Disposed 63,634 · Balance 2,082,507 F1: On December 20, 2024, Graf Acquisition Partners IV LLC (the "Sponsor") distributed 63, 634 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") to Christine Low, Franklin FTX I, L.P., and Andrew Bail, each a member of the Sponsor and initially entitled to the distribution of 15% of the original shares of common stock held by the Sponsor, which were issued upon the conversion of the shares of Class B common stock of Graf Acquisition Corp. IV, upon September 29, 2024, the one-year anniversary of the closing of the business combination between Graf Acquisition Corp. IV and the Issuer, and the additional parties thereto. F2: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. |
| Private Placement WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2028-09-29 | Direct | 1,145,831 |
Reported balance
After 2024-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-20 · Disposition to issuer · Disposed 757,942 · Balance 1,145,831 F3: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F2: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. |
| Working Capital WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2028-09-29 | Direct | 96,472 |
Reported balance
After 2024-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-20 · Disposition to issuer · Disposed 93,334 · Balance 96,472 F4: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F2: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 20, 2024, Graf Acquisition Partners IV LLC (the "Sponsor") distributed 63, 634 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") to Christine Low, Franklin FTX I, L.P., and Andrew Bail, each a member of the Sponsor and initially entitled to the distribution of 15% of the original shares of common stock held by the Sponsor, which were issued upon the conversion of the shares of Class B common stock of Graf Acquisition Corp. IV, upon September 29, 2024, the one-year anniversary of the closing of the business combination between Graf Acquisition Corp. IV and the Issuer, and the additional parties thereto.
F2: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor.
F3: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer.
F4: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2024 Filed Dec 26, 2024 19:20 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerWorking Capital Warrants · Derivative | 93,334 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-112773 · ownership.xml · derivative · entry 3 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,472 Underlying: Common Stock · 93,334 shares Expires 2028-09-29 F4 · kind: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F4 · price: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 19:20 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerPrivate Placement Warrants · Derivative | 757,942 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-112773 · ownership.xml · derivative · entry 2 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,145,831 Underlying: Common Stock · 757,942 shares Expires 2028-09-29 F3 · kind: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F3 · price: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 19:20 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | OtherCommon Stock | 63,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-112773 · ownership.xml · nonDerivative · entry 1 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,082,507 F1 · kind: On December 20, 2024, Graf Acquisition Partners IV LLC (the "Sponsor") distributed 63, 634 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") to Christine Low, Franklin FTX I, L.P., and Andrew Bail, each a member of the Sponsor and initially entitled to the distribution of 15% of the original shares of common stock held by the Sponsor, which were issued upon the conversion of the shares of Class B common stock of Graf Acquisition Corp. IV, upon September 29, 2024, the one-year anniversary of the closing of the business combination between Graf Acquisition Corp. IV and the Issuer, and the additional parties thereto. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 18, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerWorking Capital Warrants · Derivative | 266,667 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · derivative · entry 8 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,806 Underlying: Common Stock · 266,667 shares Expires 2028-09-29 F6 · kind: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F6 · price: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 18, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerPrivate Placement Warrants · Derivative | 891,696 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · derivative · entry 7 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,903,773 Underlying: Common Stock · 891,696 shares Expires 2028-09-29 F5 · kind: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F5 · price: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 18, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | OtherCommon Stock | 110,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · nonDerivative · entry 3 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,146,141 F4 · kind: On December 17, 2024, the Sponsor distributed 110,157 shares of common stock of the Issuer to Magnetar Constellation Master Fund, Ltd., Magnetar Constellation Fund II, Ltd., Magnetar Structured Credit Fund, LP, Magnetar Xing He Master Fund Ltd., Magnetar SC Fund Ltd., Purpose Alternative Credit Fund Ltd., Purpose Alternative Credit Fund - T LLC, Magnetar Lake Credit Fund LLC, Magnetar Capital Master Fund, Ltd., Magnetar Discovery Master Fund Ltd., W.I. Cook Foundation Inc., Isalea Investments LP, Edwin J. Rigaud, and Jeff Sagansky, each a member of the Sponsor and initially entitled to the distribution of 15% of the Founder Shares, upon September 29, 2024, the one-year anniversary of the Closing. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 16, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerWorking Capital Warrants · Derivative | 66,667 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · derivative · entry 6 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,473 Underlying: Common Stock · 66,667 shares Expires 2028-09-29 F6 · kind: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F6 · price: The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 16, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerPrivate Placement Warrants · Derivative | 1,212,707 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · derivative · entry 5 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,795,469 Underlying: Common Stock · 1,212,707 shares Expires 2028-09-29 F5 · kind: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F5 · price: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 16, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | OtherCommon Stock | 83,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · nonDerivative · entry 2 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,256,298 F2 · kind: On December 16, 2024, the Sponsor distributed 83,214 shares of common stock of the Issuer to ARI Founders Fund, L.P. and OC Opportunities Fund III, L.P, each a member of the Sponsor and initially entitled to the distribution of 15% of the Founder Shares, upon September 29, 2024, the one-year anniversary of the Closing. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 02, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | Disposition to issuerPrivate Placement Warrants · Derivative | 713,357 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · derivative · entry 4 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,008,176 Underlying: Common Stock · 713,357 shares Expires 2028-09-29 F5 · kind: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F5 · price: The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer. F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 02, 2024 Filed Dec 23, 2024 16:01 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | OtherCommon Stock | 97,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-111880 · ownership.xml · nonDerivative · entry 1 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,339,512 F1 · kind: On December 2, 2024, Graf Acquisition Partners IV LLC (the "Sponsor") distributed 97,232 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") to SPAC21, LLC, Claybaker LLC, and Venus Investments I LLC, each a member of the Sponsor and initially entitled to the distribution of 15% of the original shares of common stock held by the Sponsor, which were issued upon the conversion of the shares of Class B common stock of Graf Acquisition Corp. IV (the "Founder Shares"), upon September 29, 2024, the one-year anniversary of the closing of the business combination between Graf Acquisition Corp. IV and the Issuer, and the additional parties thereto (the "Closing"). F3 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 15:50 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | PurchaseCommon Stock | 450 | $3.19 | $1,435.50 |
DisclosureSEC source: 0001209191-23-057369 · doc4.xml · nonDerivative · entry 2 Graf James A · CIK 0001519672 · Interim CFO Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 693 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.03 to $3.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 15:50 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | PurchaseCommon Stock | 220 | $3.35 | $737.00 |
DisclosureSEC source: 0001209191-23-057369 · doc4.xml · nonDerivative · entry 1 Graf James A · CIK 0001519672 · Interim CFO Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.31 to $3.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 17:55 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | PurchaseCommon Stock | 13 | $2.92 | $37.90 |
DisclosureSEC source: 0001209191-23-056524 · doc4.xml · nonDerivative · entry 2 Graf James A · CIK 0001519672 · Interim CFO Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.895 to $2.98, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 17:55 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | PurchaseCommon Stock | 10 | $2.94 | $29.40 |
DisclosureSEC source: 0001209191-23-056524 · doc4.xml · nonDerivative · entry 1 Graf James A · CIK 0001519672 · Interim CFO Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10 Read SEC document |
| September 29, 2023 Filed Oct 4, 2023 06:10 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | GrantWorking Capital Warrants · Derivative | 523,140 | $1.50 Strike: $11.50 | $784,710.00 |
DisclosureSEC source: 0001104659-23-106578 · tm2327629-1_4.xml · derivative · entry 3 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,244,673 Underlying: Common Stock · 523,140 shares Expires 2028-09-29 F4 · kind: The Working Capital Warrants were issued to the Sponsor concurrently with the Closing pursuant to a working capital note between the Sponsor and the Issuer. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| September 29, 2023 Filed Oct 4, 2023 06:10 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | GrantPrivate Placement Warrants · Derivative | 4,721,533 | $1.50 Strike: $11.50 | $7,082,299.50 |
DisclosureSEC source: 0001104659-23-106578 · tm2327629-1_4.xml · derivative · entry 2 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,721,533 Underlying: Common Stock · 4,721,533 shares Expires 2028-09-29 F3 · kind: The Private Placement Warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), concurrent with the Closing, because, pursuant to their terms, their exercise was not within the control of the Reporting Persons until the Closing. The Private Placement Warrants were initially acquired in a private placement from the Issuer concurrent with Issuer's initial public offering. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| September 29, 2023 Filed Oct 4, 2023 06:10 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | OtherCommon Stock | 1,773,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-106578 · tm2327629-1_4.xml · nonDerivative · entry 1 Graf Acquisition Partners IV LLC · CIK 0001862622 · 10% owner Graf James A · CIK 0001519672 · Interim CFO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,436,744 F1 · kind: On September 29, 2023, Graf Acquisition Partners IV LLC (the "Sponsor") forfeited 1,773,631 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") held by it back to the Issuer for no consideration in connection with the closing of the Issuer's business combination transaction (the "Closing"). F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| July 14, 2021 Filed Jul 14, 2021 16:54 UTC | NKGen Biotech, Inc. GFOR · Entity 79017 | OtherCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092153 · tm2122153-2_4seq1.xml · nonDerivative · entry 1 Graf Acquisition Partners IV LLC · CIK 0001862622 · Chief Executive Officer · 10% owner Graf James A · CIK 0001519672 · Chief Executive Officer · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,210,375 F1 · kind: On July 14, 2021, Graf Acquisition Partners IV LLC (the "Sponsor") transferred 20,000 shares of common stock of the Issuer to Alexandra Lebenthal for $0.006 per share, the initial purchase price paid by the Sponsor for its shares of common stock. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:13 UTC | NKGen Biotech, Inc. GFOR · Entity 79017 | OtherCommon Stock | 22,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-075828 · tm2118241d1_4.xml · nonDerivative · entry 1 Graf Acquisition Partners IV LLC · CIK 0001862622 · Chief Executive Officer · 10% owner Graf James A · CIK 0001519672 · Chief Executive Officer · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,230,375 F1 · kind: On June 2, 2021, Graf Acquisition Partners IV LLC (the "Sponsor") forfeited at no cost 22,125 shares of common stock of the Issuer in connection with the election by the underwriters of the Issuer's initial public offering of units to exercise an option granted to them to cover over-allotments in part and not in full. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.